Nintedanib Accordpharma

Nintedanib, the active ingredient in Nintedanib Accordpharma, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib is indicated for fibrotic lung disorders and as part of combination therapy for certain lung cancers. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other agents.

Nintedanib may cause a range of adverse reactions.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Decreased appetite - Abdominal pain - Weight loss

Serious or Rare Side Effects: - Elevated liver enzymes (ALT, AST) - Bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Severe infections - Gastrointestinal perforation - Serious skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, several safety considerations should be reviewed. - Dose adjustment in hepatic impairment: reduce dose as recommended. - Monitor liver function tests: obtain baseline and periodic assessments. - Assess for bleeding risk: avoid concomitant anticoagulants when possible. - Pregnancy and breastfeeding: avoid use as safety is unknown. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Store at below 25°C: keep in the original container, protect from moisture and light.

Nintedanib can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, DOACs): heightened risk of bleeding. - Co‑administration with other VEGFR inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce exposure. - P‑gp inhibitors (e.g., verapamil): may increase plasma levels. - Diuretics: monitor for dehydration and renal function.